Takeaway
- In previously treated patients with intrahepatic cholangiocarcinoma (iCCA) harbouring FGFR2 fusions/rearrangements, futibatinib, a selective irreversible FGFR1-4 inhibitor, resulted in frequent and durable objective responses.
- Safety profile was manageable.
Why this matters
- About 15% of patients with iCCA, an aggressive malignancy with poor survival outcomes, harbour FGFR2 fusions.
- Resistance to...
